TapewireFind a company

person · Reporting owner

Tang Carolyn C.

Disclosed activity across 1 company

Tapewire entity
38803
SEC CIK
0001836662

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Arcus Biosciences, Inc.RCUS · Entity 4104General CounselJune 11, 2026June 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arcus Biosciences, Inc.

Report date June 11, 2026 · Filed June 12, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect184,607 Reported balance After 2026-06-11 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-06-11 · Exercise / conversion · Acquired 34,090 · Balance 184,607

F1: Includes 1,783 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan.

F2: Includes the unvested portion of the Reporting Person's RSU grants.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2027-08-30Direct0 Reported balance After 2026-06-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-06-11 · Exercise / conversion · Disposed 34,090 · Balance 0

F3: The option is fully vested and has been completely exercised.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 1,783 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan.

F2: Includes the unvested portion of the Reporting Person's RSU grants.

F3: The option is fully vested and has been completely exercised.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 11, 2026 Filed Jun 12, 2026 16:28 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 Exercise / conversionStock Option (Right to Buy) · Derivative 34,090 $2.57 Strike: $2.57 $87,747.66
Disclosure

SEC source: 0001836662-26-000005 · wk-form4_1781296090.xml · derivative · entry 2

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 34,090 shares

Expires 2027-08-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option is fully vested and has been completely exercised.

Read SEC document
June 11, 2026 Filed Jun 12, 2026 16:28 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 Exercise / conversionCommon Stock 34,090 $2.57 $87,747.66
Disclosure

SEC source: 0001836662-26-000005 · wk-form4_1781296090.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 184,607

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,783 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan.

F2 · balance_after: Includes the unvested portion of the Reporting Person's RSU grants.

Read SEC document
January 23, 2026 Filed Jan 26, 2026 20:21 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 96,000 $0.00 Strike: $22.13 $0.00
Disclosure

SEC source: 0001836662-26-000002 · wk-form4_1769476892.xml · derivative · entry 2

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,000

Underlying: Common Stock · 96,000 shares

Expires 2036-01-22

F3 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.

Read SEC document
January 23, 2026 Filed Jan 26, 2026 20:21 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 24,000 $0.00 $0.00
Disclosure

SEC source: 0001836662-26-000002 · wk-form4_1769476892.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,734

F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.

F2 · balance_after: Includes the unvested portion of the Reporting Person's RSU grants.

Read SEC document
December 17, 2025 Filed Dec 18, 2025 17:35 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 6,810 $22.16 $150,906.20
Disclosure

SEC source: 0001836662-25-000005 · wk-form4_1766097342.xml · nonDerivative · entry 2

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,734

F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person.

F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F4 · balance_after: Includes the unvested portion of the reporting person's RSU grants.

Read SEC document
December 16, 2025 Filed Dec 18, 2025 17:35 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 7,658 $21.88 $167,589.97
Disclosure

SEC source: 0001836662-25-000005 · wk-form4_1766097342.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 131,544

F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.42 to $22.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 1 share purchased on November 30, 2025 through the Company's Employee Stock Purchase Plan.

F4 · balance_after: Includes the unvested portion of the reporting person's RSU grants.

Read SEC document
January 23, 2025 Filed Jan 27, 2025 16:31 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 150,000 $0.00 Strike: $13.33 $0.00
Disclosure

SEC source: 0001724521-25-000021 · wk-form4_1738013456.xml · derivative · entry 2

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2035-01-22

F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company.

Read SEC document
January 23, 2025 Filed Jan 27, 2025 16:31 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 37,000 $0.00 $0.00
Disclosure

SEC source: 0001724521-25-000021 · wk-form4_1738013456.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,623

F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2025, subject to the Reporting Person's continued service to the Company.

Read SEC document
December 15, 2024 Filed Dec 17, 2024 20:36 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 Tax withholdingCommon Stock 11,339 $16.08 $182,331.12
Disclosure

SEC source: 0001724521-24-000183 · wk-form4_1734485805.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,623

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Read SEC document
June 15, 2024 Filed Jun 18, 2024 16:53 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 Tax withholdingCommon Stock 4,182 $16.97 $70,968.54
Disclosure

SEC source: 0001724521-24-000126 · wk-form4_1718744028.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,364

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

F2 · balance_after: Includes 967 shares purchased on 5/31/2024 through the Company's Employee Stock Purchase Plan.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 19:39 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 108,200 $0.00 Strike: $15.44 $0.00
Disclosure

SEC source: 0001724521-24-000027 · wk-form4_1706229568.xml · derivative · entry 2

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,200

Underlying: Common Stock · 108,200 shares

Expires 2034-01-22

F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 19:39 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 26,700 $0.00 $0.00
Disclosure

SEC source: 0001724521-24-000027 · wk-form4_1706229568.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,579

F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company.

Read SEC document
December 19, 2023 Filed Dec 20, 2023 16:10 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 Disposition to issuerCommon Stock 4,076 $18.09 $73,734.84
Disclosure

SEC source: 0001724521-23-000070 · wk-form4_1703106643.xml · nonDerivative · entry 2

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,879

F1 · shares: Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person.

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.78 to $18.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
December 18, 2023 Filed Dec 20, 2023 16:10 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 Disposition to issuerCommon Stock 3,991 $17.74 $70,800.34
Disclosure

SEC source: 0001724521-23-000070 · wk-form4_1703106643.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,955

F1 · shares: Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.45 to $17.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 44 shares purchased on 11/30/2023 through the Company's Employee Stock Purchase Plan.

Read SEC document
June 16, 2023 Filed Jun 16, 2023 20:17 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 Disposition to issuerCommon Stock 2,892 $19.35 $55,960.20
Disclosure

SEC source: 0001209191-23-038160 · doc4.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,902

F1 · shares: Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.86 to $19.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 1,255 shares purchased on 5/31/2023 through the Company's Employee Stock Purchase Plan.

Read SEC document
January 23, 2023 Filed Jan 25, 2023 17:52 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 138,200 $0.00 Strike: $22.02 $0.00
Disclosure

SEC source: 0001209191-23-004874 · doc4.xml · derivative · entry 2

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,200

Underlying: Common Stock · 138,200 shares

Expires 2033-01-22

F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2023, subject to the Reporting Person's continued service to the Company.

Read SEC document
January 23, 2023 Filed Jan 25, 2023 17:52 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 34,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-004874 · doc4.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,539

F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Company.

Read SEC document
December 16, 2022 Filed Dec 16, 2022 21:42 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 398 $31.23 $12,429.54
Disclosure

SEC source: 0001209191-22-061761 · doc4.xml · nonDerivative · entry 2

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,584

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.05 to $31.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
December 16, 2022 Filed Dec 16, 2022 21:42 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 2,125 $30.66 $65,152.50
Disclosure

SEC source: 0001209191-22-061761 · doc4.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,982

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.05 to $31.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
June 17, 2022 Filed Jun 21, 2022 16:23 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 1,073 $22.29 $23,917.17
Disclosure

SEC source: 0001209191-22-038399 · doc4.xml · nonDerivative · entry 3

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,909

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.14 to $22.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
June 17, 2022 Filed Jun 21, 2022 16:23 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 449 $21.71 $9,747.79
Disclosure

SEC source: 0001209191-22-038399 · doc4.xml · nonDerivative · entry 2

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,982

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.14 to $22.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
June 16, 2022 Filed Jun 21, 2022 16:23 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 1,400 $20.72 $29,008.00
Disclosure

SEC source: 0001209191-22-038399 · doc4.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,431

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.33 to $21.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 1,017 shares purchased on 5/31/2022 through the Company's Employee Stock Purchase Plan

Read SEC document
March 08, 2022 Filed Mar 10, 2022 17:09 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 65,000 $0.00 Strike: $33.03 $0.00
Disclosure

SEC source: 0001209191-22-017989 · doc4.xml · derivative · entry 2

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2032-03-07

F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2022, subject to the Reporting Person's continued service to the Company.

Read SEC document
March 08, 2022 Filed Mar 10, 2022 17:09 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 16,250 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017989 · doc4.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,814

F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2022, subject to the Reporting Person's continued service to the Company.

Read SEC document
December 17, 2021 Filed Dec 20, 2021 16:26 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 225 $41.42 $9,320.36
Disclosure

SEC source: 0001209191-21-070568 · doc4.xml · nonDerivative · entry 6

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,564

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F8 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $41.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
December 17, 2021 Filed Dec 20, 2021 16:26 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 171 $40.57 $6,938.02
Disclosure

SEC source: 0001209191-21-070568 · doc4.xml · nonDerivative · entry 5

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,789

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F7 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.10 to $41.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
December 17, 2021 Filed Dec 20, 2021 16:26 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 88 $39.67 $3,491.13
Disclosure

SEC source: 0001209191-21-070568 · doc4.xml · nonDerivative · entry 4

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,960

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.10 to $40.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
December 17, 2021 Filed Dec 20, 2021 16:26 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 138 $38.79 $5,352.70
Disclosure

SEC source: 0001209191-21-070568 · doc4.xml · nonDerivative · entry 3

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,048

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $39.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
December 16, 2021 Filed Dec 20, 2021 16:26 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 131 $40.46 $5,299.80
Disclosure

SEC source: 0001209191-21-070568 · doc4.xml · nonDerivative · entry 2

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,186

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.12 to $40.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
December 16, 2021 Filed Dec 20, 2021 16:26 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 356 $39.59 $14,094.61
Disclosure

SEC source: 0001209191-21-070568 · doc4.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,317

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.11 to $40.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 176 shares purchased on 11/30/2021 through the Company's Employee Stock Purchase Plan

Read SEC document
June 17, 2021 Filed Jun 21, 2021 16:54 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 1,606 $23.68 $38,030.08
Disclosure

SEC source: 0001209191-21-042082 · doc4.xml · nonDerivative · entry 3

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,362

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.395 to $24.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
June 16, 2021 Filed Jun 21, 2021 16:54 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 52 $24.77 $1,288.04
Disclosure

SEC source: 0001209191-21-042082 · doc4.xml · nonDerivative · entry 2

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,968

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.63 to $24.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
June 16, 2021 Filed Jun 21, 2021 16:54 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 1,257 $24.13 $30,331.41
Disclosure

SEC source: 0001209191-21-042082 · doc4.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,020

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 2,679 shares purchased on 5/28/2021 through the Company's Employee Stock Purchase Plan

Read SEC document
January 19, 2021 Filed Jan 20, 2021 16:16 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 75,225 $0.00 Strike: $36.73 $0.00
Disclosure

SEC source: 0001209191-21-004280 · doc4.xml · derivative · entry 2

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,225

Underlying: Common Stock · 75,225 shares

Expires 2031-01-18

F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company.

Read SEC document
January 19, 2021 Filed Jan 20, 2021 16:16 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 12,538 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-004280 · doc4.xml · nonDerivative · entry 1

Tang Carolyn C. · CIK 0001836662 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,886

F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after January 1, 2021, subject to the Reporting Person's continued service to the Company.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.